The U.S. Food and Drug Administration on November 21, 2020 issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing .
- In a clinical trial of patients with COVID-19, Monoclonal antibodies casirivimab and imdevimab, administered together, were shown to reduce COVID-19-related hospitalization.
What are Monoclonal antibodies?
- According to the US-FDA, Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.
- Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.
(Source: USFDA)
